Kyntra Bio receives Nasdaq delisting notice for failing $50M asset/revenue requirement

Filed April 9, 2026 · Period ending April 2, 2026 · ~1 min read

Key Changes

• high

  Kyntra Bio received formal notice from Nasdaq on April 2, 2026 that it no longer meets the $50M minimum requirement for total assets and revenue, triggering delisting review. The deficiency stems from FibroGen International revenue being classified as discontinued operations.

  Item 3.01 verify on EDGAR →
• high

  Company has until May 18, 2026 to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant up to 180 additional days (until September 29, 2026) to demonstrate compliance. The notice has no immediate effect on current trading status.

  Item 3.01 verify on EDGAR →
• medium

  As an alternative, Kyntra Bio is considering transferring its listing to the Nasdaq Capital Market, which has lower listing standards and would allow continued Nasdaq trading under less stringent requirements.

  Item 3.01 verify on EDGAR →